8.40
+1.82%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Puma Biotechnology
From its filings with the US Securities and Exchange Commission
Puma Biotechnology is based in Los Angeles, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PBYI. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $228.4m and net income of $31.1m. At that date it held total assets of $216.3m and shareholders' equity of $130.3m. By business, Product [Member] brought in 89.4% of revenue, followed by Royalty [Member] at 10.6%.
We are a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. We are currently commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. Additionally, we have in-licensed, and are responsible for global development and commercialization of, alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on Aurora Kinase A. Prior to our licensing alisertib from a subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”), alisertib was tested in over 1,300 patients who were treated across 22 company-sponsored trials resulting in a large, well-characterized clinical safety database. Based on information in this database, we believe alisertib has potential application in the treatment of a range of different cancer types, including hormone receptor-positive breast cancer, triple negative breast cancer and small cell lung cancer. We intend to pursue development of alisertib initially in small cell lung cancer and hormone receptor-positive breast cancer.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 21 Mar 2012
- Employees
- 179
- Website
- pumabiotechnology.com ↗
- Head office
- 10880 WILSHIRE BLVD., LOS ANGELES, CA
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Alan AuerbachChairman of the Board, President, Chief Executive Officer, Secretary, since 2010$4.0m
- Mr. Maximo NouguesChief Financial Officer$1.4m
- Mr. Douglas HuntChief Regulatory Affairs, Medical Affairs, Pharmacovigilance, and Law Officer$1.2m
- Mr. Jay MoyesLead Independent Director$160,930
- Dr. Alessandra CesanoIndependent Director$140,930
- Ms. Allison DorvalIndependent Director$143,430
- Mr. Michael MillerIndependent Director$145,930
- Dr. Adrian SenderowiczIndependent Director$153,430
- Mr. Brian StuglikIndependent Director$155,930
- Dr. Troy WilsonIndependent Director$160,930
- Mr. Mariann OhanesianInvestor Relations, since 2016
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 42
- Environment
- 47
- Social
- 29
- Governance
- 50
- Women in the workforce
- 50%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Puma Biotechnology Inc possesses several strengths that contribute to its success in the market. These strengths include:
Weaknesses
- Despite its strengths, Puma Biotechnology Inc also faces certain weaknesses that may pose challenges to its growth and competitiveness. These weaknesses include:
Opportunities
- There are several opportunities present in the market that Puma Biotechnology Inc can capitalize on. These opportunities include:
Threats
- Puma Biotechnology Inc faces certain threats that could impact its business operations and market position. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.